In Brief: Boehringer Mannheim Retavase
Executive Summary
Boehringer Mannheim Retavase: DuPont Merck will comarket the thrombolytic agent approved in October for acute myocardial infarction ("The Pink Sheet" Nov. 4, p. 5). The companies' combined sales force dedicated to Retavase will number over 400. Boehringer will donate 5% of Retavase sales to the development of a heart attack symptom awareness program that will be implemented in conjunction with the American Heart Association. The direct price to wholesalers for a Retavase kit will be $2,200...